Companies › Acepodia Biotech
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology, Other; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| ACE2016 Allogeneic gamma delta T (gdT) cell therapy engineered to target EGFR-expressing tumors | EGFR | Phase 1 | Locally Advanced Solid Tumor | Dec 2026 |
| ACE1831 Allogeneic gamma delta T cell therapy | – | Phase 1 | IgG4 Related Disease | Sep 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06415487 | ACE2016 | Phase 1 | Locally Advanced Solid Tumor | Oncology | Dec 2026 |
| NCT07061938 | ACE1831 | Phase 1 | IgG4 Related Disease | Other | Sep 2029 |
AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.